Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Tracey Schefter and Christine Fisher.

 
Connection Strength
 
 
 
2.869
 
  1. Fisher CM, Schefter TE. Profile of bevacizumab and its potential in the treatment of cervical cancer. Onco Targets Ther. 2015; 8:3425-31.
    View in: PubMed
    Score: 0.776
  2. Amini A, Robin TP, Rusthoven CG, Schefter TE, Akhavan D, Chen YJ, Glaser SM, Corr BR, Ashing KT, Fisher CM. Disparities Predict for Higher Rates of Cut-through Hysterectomies in Locally Advanced Cervical Cancer. Am J Clin Oncol. 2019 Jan; 42(1):21-26.
    View in: PubMed
    Score: 0.241
  3. Amini A, Robin TP, Stumpf PK, Rusthoven C, Schefter TE, Shinde A, Chen YJ, Glaser SM, Corr BR, Fisher CM. Rising Rates of Upfront Surgery in Early Locally Advanced Cervical Cancer: What Factors Predict for This Treatment Paradigm? Int J Gynecol Cancer. 2018 10; 28(8):1560-1568.
    View in: PubMed
    Score: 0.237
  4. Stokes WA, Robin TP, Jackson MW, Amini A, Schefter TE, Lefkowits CC, Fisher CM. Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database Analysis. Am J Clin Oncol. 2018 10; 41(10):927-932.
    View in: PubMed
    Score: 0.237
  5. Stokes WA, Jones BL, Schefter TE, Fisher CM. Impact of radiotherapy modalities on outcomes in the adjuvant management of uterine carcinosarcoma: A National Cancer Database analysis. Brachytherapy. 2018 Jan - Feb; 17(1):194-200.
    View in: PubMed
    Score: 0.225
  6. Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy. Brachytherapy. 2016 Nov - Dec; 15(6):845-850.
    View in: PubMed
    Score: 0.206
  7. Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer. Gynecol Oncol. 2016 Nov; 143(2):319-325.
    View in: PubMed
    Score: 0.205
  8. Amini A, DeWitt PE, Vinogradskiy Y, Rusthoven CG, Altunbas C, Schefter TE, Fisher CM. Should we customize PTV expansions for BMI? Daily cone beam computerized tomography to assess organ motion in postoperative endometrial and cervical cancer patients. Rep Pract Oncol Radiother. 2016 May-Jun; 21(3):195-200.
    View in: PubMed
    Score: 0.198
  9. Schubert L, Liu A, Gan G, Amini A, Hutchison R, Ernest J, Thornton D, Stoehr S, Hinman B, Stuhr K, Westerly D, Schefter T, Fisher C. Practical implementation of quality improvement for high-dose-rate brachytherapy. Pract Radiat Oncol. 2016 Jan-Feb; 6(1):34-43.
    View in: PubMed
    Score: 0.192
  10. Carlson JA, Rusthoven C, DeWitt PE, Davidson SA, Schefter TE, Fisher CM. Are we appropriately selecting therapy for patients with cervical cancer? Longitudinal patterns-of-care analysis for stage IB-IIB cervical cancer. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):786-93.
    View in: PubMed
    Score: 0.180
  11. Jackson MW, Rusthoven CG, Fisher CM, Schefter TE. Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. Onco Targets Ther. 2014; 7:751-9.
    View in: PubMed
    Score: 0.175
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2019 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)